Basis of Presentation and Summary of Significant Accounting Policies (Tables)

12 Months Ended

Dec. 31, 2024

Basis of Presentation and Summary of Significant Accounting Policies [Abstract]

Restricted Cash

The following table provides a reconciliation of the components of cash, cash equivalents and restricted cash reported in the Company’s consolidated balance sheets to the total of the amount presented in the consolidated statements of cash flows (in thousands):

	December 31,
	2024		2023
Cash and cash equivalents	$	7,261	$	6,784
Restricted cash		1,334		1,334
Total cash, cash equivalents and restricted cash presented in the consolidated statements of cash flows	$	8,595	$	8,118

Accrued Warranty Costs Activity

The activity in the warranty accrual during the years ended December 31, 2024 and 2023 is summarized as follows (in thousands):

	December 31,
	2024			2023
Balance, beginning of year	$	303		$	207
Additions		156			237
Expirations and claims satisfied		(144	)		(141	)
Total		315			303
Less current portion within accrued expenses and other current liabilities		(213	)		(180	)
Balance within deferred revenues and other liabilities	$	102		$	123

Disaggregation of Revenue

The following table presents the Company’s net revenues disaggregated by dermatology recurring procedures and dermatology procedures equipment (in thousands):

	Year Ended December 31,
	2024		2023
Dermatology recurring procedures	$	21,171	$	21,530
Dermatology procedures equipment		12,391		11,828
Total net revenues	$	33,562	$	33,358

Future Undiscounted Fixed Treatment Code Payments

The following table summarizes the Company’s expected future undiscounted fixed treatment code payments from international dermatology recurring procedures, the Company’s only long-term arrangements (in thousands):

Years ending December 31:
2025	$	1,775
2026		1,586
2027		1,323
2028		790
	$	5,474

Antidilutive Securities Excluded from Computation of Net Loss Per Share

The following potentially dilutive securities have been excluded from the computation of diluted weighted-average shares of common stock outstanding, as they would be anti-dilutive:

	December 31,
	2024		2023
Stock options		521,726		772,864
Common stock warrants		80,000		80,000
Restricted stock units		2,265		2,265
		603,991		855,129